Amgen Enbrel Patent Victory

03-JUL-20

If you own a bunch of high-quality stocks in a portfolio, good things are always happening to them, and you only find out later. Here's a case in point, Amgen just had a major patent protection victory. The stock popped up to a new all-time high of $260 per share yesterday.


Read more...

Amgen Q1 - Solid Results

07-MAY-20

Last week Amgen released solid results. Sales increased 12% year on year to $6.1bn. Some of the their up and coming blockbuster drugs had a good quarter. Repatha which treats cholesterol increased sales by 62%. That is one of their potential rockstars.


Read more...

Amgen Working To Combat Covid-19

07-APR-20

What about buying pharmaceutical stocks at a time like this? In the middle of a global pandemic of such major proportions, big money is being thrown at Covid-19 diagnostics, treatment, vaccines and immunity enhancers.


Read more...

AMGN Q4 - In Transition Period

03-FEB-20

On Thursday night Amgen released results that beat both revenue and profit forecasts. What didn't impress the market was their lower than expected guidance around future profits. The stock close down 4.5% on Friday, around half of that drop, can be attributed to the general market sell-off though.


Read more...

Amgen Buys into BeiGene

04-NOV-19

Our biotech pharma investment Amgen has made some interesting moves in the last week. As long-time holders of this stock know, it owns a wide portfolio of patented drugs for treating inflammation and arthritis, cardiovascular disease, cancer, migraines, bone injuries and skin disorders.


Read more...

Amgen Q3 - Biosimilar Continues to Grow

30-OCT-19

The world's largest biotech company, Amgen released its third-quarter earnings that beat the streets expectations. The company saw strong volume growth for the seventh consecutive quarter which can be attributable to new drug launches like migraines drug Aimovig and the launch of biosimilars including Kanjinti for breast cancer.


Read more...

Amgen Buys Otezla

27-AUG-19

There was good news yesterday from our recommended portfolio holding, biotech pharma company Amgen. They announced that they will buy the psoriasis drug Otezla from Celgene for $13.4 billion in cash.


Read more...

Amgen Q2 - Beats Expectations

01-AUG-19

What's going on at Amgen? This biotech company is also widely held in our client base, and its share price has underperformed a bit lately. The stock price reached $210 late last year, but has since drifted lower to around $180 per share.


Read more...

Amgen's New Lung and Colon cancer

27-JUN-19

Our most important role at Vestact is to closely monitor the stocks that our clients own. Pharmaceutical giant Amgen is held by most of our New York customers. Its share price has been drifting around lately, and closed at $183.17 last night. In fact, there is lots of good stuff going on at Amgen. It's just that some of their current big-selling drugs are reporting declining sales, and their newer ones are taking time to gain traction. Here are two stories that underline why this stock is a good one to own.


Read more...

Amgen Q1 - Pause Before New Drugs Take Off

06-MAY-19

Last week Vestact's direct exposure to the pharmaceutical industry, Amgen, reported their Q1 numbers. Currently, the company is in a bit of no-mans land, where some of their big-name patents have recently expired, and the company is waiting for their new big-name drugs to ramp up in scale.


Read more...

Amgen's Fight with Novartis

09-APR-19

Vestact recommended pharma company Amgen has an extremely promising drug called Erenumab (trade name Aimovig) which is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraines. It was approved by the US FDA in 2018.


Read more...

Amgen Q4 - Mix of Old and New Drugs

04-FEB-19

Last week our favoured biotech stock, Amgen, released results for the fourth quarter and full year 2018. As we have alluded to before, Amgen is going through a phase where a few of their blockbuster drugs are slowing down because of off-patent competition. At the same time they are pushing new exciting drugs into the market. That is not always as easy as it sounds, even if you assume the drug works really well. You still need to convince the doctors, insurers and hospitals to endorse the product.


Read more...

Amgen Q3 - Beats expectations

31-OCT-18

Amgen is another core holding in Vestact US portfolios, and had results out after the bell last night. As you know, it is one of the world's leading biotechnology companies, with a focus on cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.


Read more...

Amgen invests in Oxford Nanopore

24-OCT-18

When there is a lot going on in the general news, it's useful to refocus on company specific updates. After all, we invest in actual enterprises which do useful things in the real world, and get paid.


Read more...

Amgen's new Drugs

25-SEP-18

Amgen is a core holding in Vestact US portfolios. It is one of the world's leading biotechnology companies, and it closed at a lifetime high of $207.21 last night, giving it a market capitalisation of $134 billion.


Read more...

Older stories...

Newsletter Sign Up

Sign up for our free daily market newsletter.

Paul Theron's Tweets

Byron Lotter's Tweets

Michael Treherne's Tweets

Bright Khumalo's Tweets